Protein alteration contributes to degeneration of neuronal populations in Huntington s disease
Protein alteration in the family of lamins causes several diseases, known as laminopathies, such as progeria or precocious aging.
A study in which UB researchers have taken part states that alterations in the levels of one of these proteins, lamin B1, contribute to the degeneration of different brain neuronal populations in Huntington s disease. Caused by a mutation in the huntingtin gene, this pathology features involuntary movements, cognitive deficit, and psychiatric disorders, and has no cure yet.
According to the study, published in the journal
EMBO Molecular Medicine, these results open new therapeutic pathways for the treatment of this disease, since research shows pharmacological normalization of levels of lamin B1 improves the cognitive symptoms in a transgenic model of the disease.
From left to right: Carla Castany-Pladevall, Esther Pérez-Navarro and Arantxa Golbano.
From left to right: Rafael Alcalá-Vida and Marta Garcia-Forn.
These images show the nucleus of neurons in the CA1 region of the hippocampus with a marker for lamina B1. It shows the altered morphology of the nuclei of neurons in the R6/1 mouse, a model of Huntington’s disease.
Protein alteration in the family of lamins causes several diseases, known as laminopathies, such as progeria or precocious ageing. A study in which UB researchers have taken part states that alterations in the levels of one of these proteins, lamin B1, contribute to the degeneration of different brain neuronal populations in Huntington’s disease. Caused by a mutation in the huntingtin gen, this pathology features involuntary movements, cognitive deficit and psychiatric disorders, and has no cure yet. According to the study, published in the journal EMBO Molecular Medicine, these results open new therapeutic pathways
Common Scientific Advisory Board (SAB) between CRKI and KCCC
A common international Scientific Advisory Board between Cancer Research KI and the Karolinska Comprehensive Cancer Center (KCCC) has been established. The board of directors of the KCCC, representing both the Karolinska Institute and The Karolinska University Hospital, aimed to incorporate advisory members with broad expertise in clinical, basic and caring cancer research; covering a varied set of cancer subdisciplines.
This common SAB will be able to advise on matters including, but not limited to, the long-term strategic development of research, education, care and prevention within cancer for both Cancer Research KI and the CCC. The current members of the SAB are listed below in the table.
Search jobs 18-Jan-2021 Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe
BARCELONA, Spain & REDWOOD CITY, Calif. (BUSINESS WIRE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, have agreed to enter into a partnership to establish in-house liquid biopsy testing services, using Guardant Health’s industry-leading proprietary digital sequencing platform, at VHIO’s facility in Barcelona, Spain.
The service is expected to become operational in 2021 and will be available for clinical research and clinical care starting with private patients, followed by expansion into the public healthcare system over time.
Posted on 8372
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, have agreed to enter into a partnership to establish in-house liquid biopsy testing services, using Guardant Health’s industry-leading proprietary digital sequencing platform, at VHIO’s facility in Barcelona, Spain.
The service is expected to become operational in 2021 and will be available for clinical research and clinical care starting with private patients, followed by expansion into the public healthcare system over time.
“We are pleased to announce this partnership with VHIO which will bring liquid biopsy comprehensive genomic testing to more cancer patients in Spain and beyond,” said Helmy Eltoukhy, Guardant Health CEO. “Our vision is that all cancer patients globally have access to state-of-the-art diagnost